Savas Medikal was founded in 1993 and is a well-established and successful family business with a large market share and longstanding experience in the medical devices segment. The company is headquartered in Istanbul with an extensive distributor network that comprises four branches and more than 40 distributors throughout Turkey. Savas Medikal is a market leader in POC testing, mainly in the fields of cardiology, intensive care, respiratory diagnostics and biochemistry, and offers a range of innovative products for neonatal care.

In Turkey, 1.2 million children are born every year. The CE marking is valid in the country, but all medtech products must be registered with the country's “Device Tracking System”, which, in Calmark's assessment, may take 1–2 months from the submission.

“I am extremely pleased to have concluded this distributor agreement, because Savas Medikal is a perfect fit for the Neo-Bilirubin product; the company already possesses the appropriate customer base, appreciates the value of point-of-care testing, and is in no doubt that our product will make a great difference in healthcare,” says Magdalena Tharaldsen, Director International Business Development at Calmark. “I look forward to enjoying a fruitful collaboration with this highly motivated distributor!”

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 13-03-2023 16:50 CET.

For more information about Calmark Sweden AB, please contact:

Camilla Arneving, Acting CEO
Telefon: +46 (0)10 204 01 50
E-post: camilla.arneving@calmark.se
www.calmark.se 

Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first CE marked test, Neo-Bilirubin, measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.